<DOC>
	<DOCNO>NCT01479881</DOCNO>
	<brief_summary>The purpose study investigate effect steady-state concentration TMC435 ( administer day ) single-dose pharmacokinetics immunosuppressant cyclosporine tacrolimus healthy participant . Cyclosporine tacrolimus immunosuppressant use prevent transplant rejection may therefore potentially coadministered TMC435 patient infect hepatitis C virus undergo liver transplantation . We also explore short-term safety tolerability follow coadministration TMC435 steady-state ( 1 ) cyclosporine ( 2 ) tacrolimus single dose healthy participant . Steady-state term mean drug give long enough plasma concentration remain subsequent dose . Pharmacokinetics ( PK ) mean drug absorb bloodstream , distribute body eliminate body .</brief_summary>
	<brief_title>A Study Healthy Participants Investigating Effect TMC435 Pharmacokinetics Immunosuppressants Cyclosporine Tacrolimus</brief_title>
	<detailed_description>TMC435 protease inhibitor ( PI ) investigate treatment chronic hepatitis C virus ( HCV ) infection , combination Peg-IFN ( pegylated interferon ) RBV ( ribavirin ) . This Phase I , open-label ( participant investigator know name medication give certain moment ) trial 28 healthy participant investigate effect TMC435 steady-state single dose pharmacokinetics immunosuppressant cyclosporine tacrolimus . The trial population consist total 28 healthy participant , equally divide 2 panel . In Panel 1 , participant receive 2 treatment : single 100-mg dose cyclosporine Day 1 TMC435 150 mg daily 10 day Days 1 10 , coadministered single 100-mg dose cyclosporine Day 7 . In Panel 2 , participant receive 2 treatment : single 2-mg dose tacrolimus Day 1 TMC435 150 mg day 12 day Days 1 12 , coadministered single 2-mg dose tacrolimus Day 7 . Safety tolerability assess study period follow . Blood urine safety sample , electrocardiogram ( ECG ) vital sign ( blood pressure heart rate ) take screening , Day1 , Day 2 ( panel 1 ) , Day 7 ( panel 2 ) , Day 8 ( panel 2 ) follow-up visit 5 7 day last TMC435 intake .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Immunosuppressive Agents</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<mesh_term>Simeprevir</mesh_term>
	<criteria>Women must postmenopausal least 2 year , OR surgically sterile , OR heterosexually active duration study vasectomize partner OR childbearing potential heterosexually active , practice highly effective method birth control entry , agree continue use method contraception throughout study least 30 day last administration study drug ( ) . A positive Human Immunodeficiency Virus ( HIV ) 1 HIV2 test screening ; A positive Hepatitis A , B C test screening</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>Hepatitis C Virus</keyword>
	<keyword>TMC435</keyword>
	<keyword>TMC435-TiDP16-C120</keyword>
	<keyword>TMC435-C120</keyword>
	<keyword>HCV</keyword>
	<keyword>Hepatitis C</keyword>
	<keyword>Hep C</keyword>
	<keyword>Healthy participant</keyword>
</DOC>